Company: NCEL
Filing Date: 2025-09-03
Form Type: F-4/A
Source: 0001213900-25-084157
Chunk: 292

Company: NewcelX Ltd.
Filing Date: 2025-09-03
Form: F-4/A
Chunk 292
---
 reverse merger with a company that had sufficient funds and a promising, complementary research and development strategy. Given the imminent risks of delisting and running out of cash by October 2024, the NLS Board believed it needed to make a swift decision. The NLS Board discussions included the evaluation and consideration of a variety of strategic opportunities to increase the size of NLS and the potential benefits and risks of such strategic transactions. In this regard, NLS’s management considered the feasibility and attractiveness of a potential transaction between NLS and Kadimastem. On June 29, 2024, NLS engaged H.C. Wainwright & Co. LLC, a U.S. investment bank, or HCW, to assist the NLS management team in exploring strategic transactions. The lead HCW investment banker was Oded Spindel. Pursuant to the finders agreement dated June 28, 2024, or the Finders Agreement, by and between NLS and HCW, HCW agreed to directly introduce NLS to certain potential third party entities in the Finders Agreement, which may be supplemented by mutual consent between NLS and HCW, for a potential merger, acquisition, business combination, collaboration or similar strategic transaction between the NLS and any such entity listed in the Finders Agreement. Further, the Finders Agreement states that in the event NLS enters into a binding term sheet or similar agreement with respect to a potential merger, acquisition, business combination, collaboration or similar strategic transaction by NLS with each or any of the entities listed in the Finders Agreement during the term of the Finders Agreement, NLS shall pay HCW, within seven calendar days of the closing date of such transaction, a cash fee equal to $250,000 for each such transaction and shall issue to HCW (or its designees) warrants to purchase $500,000 worth of NLS Common Shares. Such warrants shall be in a customary form, will have a term of five years from the issuance date and an exercise price per share equal to the NLS Common Shares market price on Nasdaq immediately prior to the public announcement of such transaction. Although the Finders Agreement has terminated on June27, 2025, NLS is required to make payments under the Finders Agreement of a cash fee up to $250,000 and warrants to purchase $500,000 worth of NLS Common Shares with an exercise price per share equal to the NLS Common Shares market price on Nasdaq immediately prior to the public announcement of such transaction